Cai-Xia Gao1, Bin Chen2, Hui-Kang Xie1, Chao-Nan Han2, Jie Luo2. 1. Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China. 2. Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
Abstract
BACKGROUND: This study aimed to define whether sirtuin 2 (SIRT2) expression levels are related to the prognosis of non-small cell lung cancer (NSCLC) patients. METHODS: A survival analysis was carried out using the Kaplan-Meier (KM) plotter database. Immunohistochemical staining was performed and KM's method was used to estimate the survival rates for SIRT2 expression in 72 clinical samples. RESULTS: A survival analysis of 1,926 NSCLC patients showed that patients with low SIRT2 expression levels had significantly longer overall survival (OS) than those with high SIRT2 expression levels (P=0.0077; HR =1.19). In 72 non-metastasized NSCLC tissues, the positive rate of SIRT2 expression was 90.3% (65/72), among which, the positive expression rates of squamous cell carcinoma (SCC) and adenocarcinoma (ADC) were 96.4% (27/28) and 85.4% (35/41), respectively. Survival analysis showed that patients with low SIRT2 expression levels had significantly longer median survival time (MST) than those with high SIRT2 expression levels (15.0 versus 14.0 months, P=0.029). Furthermore, the results of subgroup analysis demonstrated patients with low SIRT2 expression levels had significantly longer survival time in ADC group (15.0 versus 12.0 months, P=0.022), but there wasn't significant difference in SCC group (15.0 versus 14.0 months, P=0.932). A multivariate Cox proportional hazards model, which included gender, age, TNM stage, differentiation and SIRT2 expression, showed that SIRT2 expression was an independent factor related to prognosis [HR =1.903, 95% confidence interval (95% CI): 1.085-3.339, P=0.025]. CONCLUSIONS: SIRT2 expression levels were significantly related to the survival time of patients with lung ADC but not SCC. Our study indicated SIRT2 was perhaps a specific prognostic biomarker for non-metastasized lung ADC. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: This study aimed to define whether sirtuin 2 (SIRT2) expression levels are related to the prognosis of non-small cell lung cancer (NSCLC) patients. METHODS: A survival analysis was carried out using the Kaplan-Meier (KM) plotter database. Immunohistochemical staining was performed and KM's method was used to estimate the survival rates for SIRT2 expression in 72 clinical samples. RESULTS: A survival analysis of 1,926 NSCLC patients showed that patients with low SIRT2 expression levels had significantly longer overall survival (OS) than those with high SIRT2 expression levels (P=0.0077; HR =1.19). In 72 non-metastasized NSCLC tissues, the positive rate of SIRT2 expression was 90.3% (65/72), among which, the positive expression rates of squamous cell carcinoma (SCC) and adenocarcinoma (ADC) were 96.4% (27/28) and 85.4% (35/41), respectively. Survival analysis showed that patients with low SIRT2 expression levels had significantly longer median survival time (MST) than those with high SIRT2 expression levels (15.0 versus 14.0 months, P=0.029). Furthermore, the results of subgroup analysis demonstrated patients with low SIRT2 expression levels had significantly longer survival time in ADC group (15.0 versus 12.0 months, P=0.022), but there wasn't significant difference in SCC group (15.0 versus 14.0 months, P=0.932). A multivariate Cox proportional hazards model, which included gender, age, TNM stage, differentiation and SIRT2 expression, showed that SIRT2 expression was an independent factor related to prognosis [HR =1.903, 95% confidence interval (95% CI): 1.085-3.339, P=0.025]. CONCLUSIONS: SIRT2 expression levels were significantly related to the survival time of patients with lung ADC but not SCC. Our study indicated SIRT2 was perhaps a specific prognostic biomarker for non-metastasized lung ADC. 2019 Journal of Thoracic Disease. All rights reserved.
Authors: Sylvia C Dryden; Fatimah A Nahhas; James E Nowak; Anton-Scott Goustin; Michael A Tainsky Journal: Mol Cell Biol Date: 2003-05 Impact factor: 4.272
Authors: Moon Hee Yang; Gaelle Laurent; Alexandra S Bause; Robert Spang; Natalie German; Marcia C Haigis; Kevin M Haigis Journal: Mol Cancer Res Date: 2013-05-30 Impact factor: 5.852
Authors: P Y Liu; N Xu; A Malyukova; C J Scarlett; Y T Sun; X D Zhang; D Ling; S-P Su; C Nelson; D K Chang; J Koach; A E Tee; M Haber; M D Norris; C Toon; I Rooman; C Xue; B B Cheung; S Kumar; G M Marshall; A V Biankin; T Liu Journal: Cell Death Differ Date: 2012-11-23 Impact factor: 15.828
Authors: Anna R McCarthy; Marijke C C Sachweh; Maureen Higgins; Johanna Campbell; Catherine J Drummond; Ingeborg M M van Leeuwen; Lisa Pirrie; Marcus J G W Ladds; Nicholas J Westwood; Sonia Laín Journal: Mol Cancer Ther Date: 2013-01-15 Impact factor: 6.261
Authors: Ivana Grbesa; María J Pajares; Elena Martínez-Terroba; Jackeline Agorreta; Ana-Matea Mikecin; Marta Larráyoz; Miguel A Idoate; Koraljka Gall-Troselj; Ruben Pio; Luis M Montuenga Journal: PLoS One Date: 2015-04-27 Impact factor: 3.240